A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia
| Autor: | Abhishek Mamarde, Amrita Prakash Singam, Prakash B Behere |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Psychiatry
medicine.medical_specialty atypical antipsychotic Risperidone medicine.drug_class RC435-571 Atypical antipsychotic Typical antipsychotic medicine.disease Clinical study schizophrenia Clinical Psychology Psychiatry and Mental health Schizophrenia Internal medicine medicine In patient Original Article Single blind Chlorpromazine Psychology medicine.drug |
| Zdroj: | Indian Journal of Psychological Medicine, Vol 33, Iss 2, Pp 134-140 (2011) Indian Journal of Psychological Medicine |
| ISSN: | 0253-7176 |
| Popis: | Objectives: The present study was undertaken to test the comparative efficacy of chlorpromazine and risperidone in patients of schizophrenia in a tertiary care hospital of Maharashtra. Materials and Methods: About 100 subjects of either sex between 15 and 75 years of age were randomly assigned either chlorpromazine or risperidone. Only those patients were included who met International Classification of Diseases 10 revision criteria by World Health Organization. To avoid bias, the test drugs were coded as A and B. The study coordinator was unaware of the prescribed drugs; however, the prescribing psychiatrist knew about the drug treatment. Results: Both chlorpromazine and risperidone significantly decreased the mean score of positive and general symptoms in patients of schizophrenia. Although chlorpromazine decreased the mean score of negative symptoms, it was not statistically significant. Risperidone reduced the mean score of negative symptoms to a significant extent. The cost (Rs. 3000-4000) of risperidone was more than the cost (Rs. 700-1000) of chlorpromazine per patient per annum. The dropouts were less (25%) in the risperidone group than in the chlorpromazine group (75%). The more purchase of risperidone than of chlorpromazine was observed in our study. Conclusion: The response rates for positive and general symptoms were found to be equal for both chlorpromazine and risperidone. However, risperidone was found to be more effective than chlorpromazine in treating negative symptoms. The dropout rate was less in the risperidone group than in the chlorpromazine group. The compliance was also better in the risperidone group, even though the cost of risperidone was more than that of chlorpromazine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|